Wordt geladen...
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe...
Bewaard in:
Gepubliceerd in: | Breast Cancer Res Treat |
---|---|
Hoofdauteurs: | , , , , , , , , , , , , , |
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
2015
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4947530/ https://ncbi.nlm.nih.gov/pubmed/26708471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3656-0 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|